000162813 001__ 162813
000162813 005__ 20230915092408.0
000162813 0247_ $$2doi$$a10.1002/ana.26128
000162813 0247_ $$2pmid$$apmid:34021620
000162813 0247_ $$2ISSN$$a0364-5134
000162813 0247_ $$2ISSN$$a1531-8249
000162813 0247_ $$2altmetric$$aaltmetric:106279827
000162813 037__ $$aDZNE-2021-01468
000162813 041__ $$aEnglish
000162813 082__ $$a610
000162813 1001_ $$0P:(DE-HGF)0$$aHeinzel, Sebastian$$b0
000162813 245__ $$aGut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease.
000162813 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2021
000162813 3367_ $$2DRIVER$$aarticle
000162813 3367_ $$2DataCite$$aOutput Types/Journal article
000162813 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1684911306_29136$$xErratum/Correction
000162813 3367_ $$2BibTeX$$aARTICLE
000162813 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162813 3367_ $$00$$2EndNote$$aJournal Article
000162813 520__ $$aAlterations of the gut microbiome in Parkinson disease (PD) have been repeatedly demonstrated. However, little is known about whether such alterations precede disease onset and how they relate to risk and prodromal markers of PD. We investigated associations of these features with gut microbiome composition.Established risk and prodromal markers of PD as well as factors related to diet/lifestyle, bowel function, and medication were studied in relation to bacterial α-/β-diversity, enterotypes, and differential abundance in stool samples of 666 elderly TREND (Tübingen Evaluation of Risk Factors for Early Detection of Neurodegeneration) study participants.Among risk and prodromal markers, physical inactivity, occupational solvent exposure, and constipation showed associations with α-diversity. Physical inactivity, sex, constipation, possible rapid eye movement sleep behavior disorder (RBD), and smoking were associated with β-diversity. Subthreshold parkinsonism and physical inactivity showed an interaction effect. Among other factors, age and urate-lowering medication were associated with α- and β-diversity. Constipation was highest in individuals with the Firmicutes-enriched enterotype, and physical inactivity was most frequent in the Bacteroides-enriched enterotype. Constipation was lowest and subthreshold parkinsonism least frequent in individuals with the Prevotella-enriched enterotype. Differentially abundant taxa were linked to constipation, physical inactivity, possible RBD, smoking, and subthreshold parkinsonism. Substantia nigra hyperechogenicity, olfactory loss, depression, orthostatic hypotension, urinary/erectile dysfunction, PD family history, and the prodromal PD probability showed no significant microbiome associations.Several risk and prodromal markers of PD are associated with gut microbiome composition. However, the impact of the gut microbiome on PD risk and potential microbiome-dependent subtypes in the prodrome of PD need further investigation based on prospective clinical and (multi)omics data in incident PD cases. ANN NEUROL 2021;90:E1-E12.
000162813 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000162813 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162813 7001_ $$00000-0003-2916-7018$$aAho, Velma T E$$b1
000162813 7001_ $$0P:(DE-HGF)0$$aSuenkel, Ulrike$$b2
000162813 7001_ $$0P:(DE-HGF)0$$avon Thaler, Anna-Katharina$$b3
000162813 7001_ $$0P:(DE-2719)9000366$$aSchulte, Claudia$$b4$$udzne
000162813 7001_ $$0P:(DE-2719)2812432$$aDeuschle, Christian$$b5$$udzne
000162813 7001_ $$aPaulin, Lars$$b6
000162813 7001_ $$aHantunen, Sari$$b7
000162813 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b8$$udzne
000162813 7001_ $$0P:(DE-HGF)0$$aEschweiler, Gerhard W$$b9
000162813 7001_ $$0P:(DE-HGF)0$$aMaetzler, Walter$$b10
000162813 7001_ $$0P:(DE-HGF)0$$aBerg, Daniela$$b11
000162813 7001_ $$aAuvinen, Petri$$b12
000162813 7001_ $$00000-0001-9502-7131$$aScheperjans, Filip$$b13
000162813 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.26128$$gVol. 90, no. 3$$n3$$pE1-E12$$tAnnals of neurology$$v90$$x1531-8249$$y2021
000162813 7870_ $$0DZNE-2020-01303$$aHeinzel, Sebastian et.al.$$dHoboken, NJ : Wiley-Blackwell, 2020$$iRelatedTo$$r$$tRetracted: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease.
000162813 8564_ $$uhttps://pub.dzne.de/record/162813/files/DZNE-2021-01468.pdf$$yOpenAccess
000162813 8564_ $$uhttps://pub.dzne.de/record/162813/files/DZNE-2021-01468.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162813 909CO $$ooai:pub.dzne.de:162813$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162813 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000366$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000162813 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812432$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000162813 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000162813 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000162813 9141_ $$y2021
000162813 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000162813 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000162813 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000162813 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-03$$wger
000162813 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000162813 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162813 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-30$$wger
000162813 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2021$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-30
000162813 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN NEUROL : 2021$$d2022-11-30
000162813 9201_ $$0I:(DE-2719)5000055$$kAG Berg ; AG Berg$$lParkinson's Disease Genetics$$x0
000162813 9201_ $$0I:(DE-2719)1240004$$kBiobanking Facility Tübingen$$lBiobanking Facility Tübingen$$x1
000162813 9201_ $$0I:(DE-2719)1210000$$kAG Gasser 1$$lParkinson Genetics$$x2
000162813 980__ $$ajournal
000162813 980__ $$aVDB
000162813 980__ $$aI:(DE-2719)5000055
000162813 980__ $$aI:(DE-2719)1240004
000162813 980__ $$aI:(DE-2719)1210000
000162813 980__ $$aUNRESTRICTED
000162813 9801_ $$aFullTexts